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Internationally, most atrial fibrillation (AF) management guidelines recommend 3 
opportunistic screening for AF in people aged ≥65 years, and oral anticoagulant (OAC) 4 
treatment for those at high stroke risk (CHA₂DS₂-VA ≥2). However, gaps remain in screening 5 
and treatment. 6 
Methods and Results 7 
General practitioners/nurses at practices in rural Australia(n=8) screened eligible patients 8 
(aged ≥65 years without AF) using a smartphone electrocardiogram during practice visits. 9 
eHealth tools included electronic prompts, guideline-based electronic decision support, and 10 
regular data reports. Clinical audit tools extracted deidentified data. Results were compared 11 
to an earlier study in metropolitan practices(n=8) and non-randomised control 12 
practices(n=69). Cost-effectiveness analysis compared population-based screening to no 13 
screening and included screening, treatment and hospitalisation costs for stroke and serious 14 
bleeding events. Patients (n=3,103, 34%) were screened (mean age 75.1±6.8 years, 47% 15 
male) and 36(1.2%) new AF cases were confirmed (mean age 77.0 years, 64% male, mean 16 
CHA₂DS₂-VA=3.2). OAC treatment rates for patients with CHA₂DS₂-VA≥2 were 82% (screen-17 
detected) versus 74% (pre-existing AF)(p=NS), similar to metropolitan and non-randomised 18 
control practices. The incremental cost-effectiveness ratio (ICER) for population-based 19 
screening was AU$16,578/quality adjusted life year gained and AU$84,383/stroke 20 
prevented compared to no screening. National implementation would prevent 147 21 





An AF screening program in rural practices, supported by eHealth tools, screened 34% of 2 
eligible patients and was cost-effective. OAC treatment rates were relatively high at 3 
baseline, trending upwards during the study. Increasing the proportion screened would 4 
prevent many more strokes with minimal ICER change. eHealth tools, including data reports, 5 
may be a valuable addition to future programs. 6 
Clinical Trial Registration 7 
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Clinical Perspective 1 
What is new? 2 
• This study extends the evidence base in rural areas by demonstrating that a screening 3 
program using eHealth tools in the rural general practice setting can successfully screen 34% 4 
of eligible atrial fibrillation (AF) patients with guideline-indicated treatment rates >80% for 5 
screen-detected AF cases.  6 
• Economic modelling showed the program was cost-effective compared to no screening.  7 
• Oral anticoagulant (OAC) treatment rates for eligible patients were higher than previous 8 
studies at baseline (>70%) and were trending upwards during the study (around 80%).  9 
What are the clinical implications?  10 
• eHealth tools, particularly customised data reports as part of an audit and feedback system, 11 
may be a valuable addition to screening programs 12 
• Half the practices screened 40-50% of eligible patients, suggesting this may represent a 13 
‘ceiling’ of patients captured by opportunistic AF screening programs in the general practice 14 
setting. 15 
• Increasing the proportion screened would prevent many more strokes with minimal change 16 
to the incremental cost-effectiveness ratio (ICER).  17 




Internationally, opportunistic screening for atrial fibrillation (AF) in people aged ≥65 years is 2 
now recommended by most guidelines.1, 2 Single-timepoint screening detects undiagnosed 3 
AF, which is often asymptomatic, in approximately 1.4% of people in this age group.3 4 
Guidelines generally recommend treatment with oral anticoagulants (OACs),1, 2 which can 5 
reduce the risk of AF-related stroke by 64% for those at high risk (“sexless” CHA₂DS₂-VA risk 6 
score ≥2).4 7 
Large gaps in screening and treatment exist in practice. A survey conducted by The 8 
Economist in 2017 reported that only 11% of people aged ≥65 years were screened in 9 
Australian general practices in the previous fortnight.5 Our previous 2018 study using 10 
eHealth tools conducted in metropolitan general practices increased screening to 16% of 11 
eligible patients.6 In terms of treatment, rates have historically been 50-60%. However, 12 
since non-vitamin K dependent OAC (NOAC) medicines were introduced, an increase in 13 
treatment rates has been reported in Europe (>77% in England7 and >65% in Denmark8). 14 
This trend was also reflected in our 2018 metropolitan study, which reported a treatment 15 
rate of 71% for those diagnosed with AF prior to the study, increasing to >80% for those 16 
diagnosed during the study period.6 17 
Australians living in rural areas have more limited access to health services and worse 18 
cardiovascular outcomes.9 The ratio of GPs, specialists, and nurses per capita of population 19 
are significantly lower in rural areas than in metropolitan areas, and access to specialist 20 
cardiac care is more limited.10, 11 Approximately 25% of the rural population suffers from 21 
cardiovascular diseases compared with 20% in metropolitan areas and the likelihood of 22 
hospitalisation and death resulting from cardiac events increases with the distance from 23 
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metropolitan areas.12 General practices play a key role in supporting cardiac health in rural 1 
areas as they tend to provide a broader range of community services compared to 2 
metropolitan practices.13  3 
Several of our previous studies showed opportunistic screening in primary care by general 4 
practitioners (GPs) and nurses was feasible.6, 14, 15 A suite of customised eHealth tools, 5 
including an automated prompt and electronic decision support, were found to be 6 
promising.6 These tools have been refined and enhanced with a quality improvement (QI) 7 
focus,16, 17 and are designed to support all stages of screening.  8 
This study aims to improve the proportion of patients screened and treated for AF using the 9 
refined eHealth tools and to inform strategies on AF screening implementation in the rural 10 
setting. In addition, this study provides the first cost-effectiveness analysis in Australian 11 
general practice.  12 
Methods 13 
This study was conducted in a convenience sample of 8 rural general practices from 14 
September 2018-July 2019 in rural New South Wales, Australia. Practices were required to 15 
be located outside a major city (generally categorised under the Australian Statistical 16 
Geography Standard - Remoteness Area ASGS-RA 201618 code 2 “inner regional Australia”) 17 
and were recruited by advertisements in Primary Health Network newsletters and by word-18 
of-mouth. Participating practices provided written informed consent and patients provided 19 
oral consent for screening. This study was approved by the University of Sydney Human 20 
Research Ethics Committee (Project no. 2017/1017). Clinical trial registration: 21 
ACTRN12618000004268. The data and materials will not be made available to other 22 
researchers as data sharing is not permitted by our ethics committee approval. Researchers 23 
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interested in the data, methods, or analysis can contact the corresponding author for more 1 
information. 2 
The methods for this study have been previously described in detail.17 Briefly, GPs and/or 3 
practice nurses offered screening for AF with smartphone handheld single lead 4 
electrocardiograms (iECGs) (KardiaMobile) to eligible patients attending the practice for any 5 
reason. Eligible patients were those aged ≥65 years without an existing AF diagnosis who 6 
had not already been screened with the iECG within the past 12 months. All follow-up for 7 
those with abnormal screening results according to the iECG app (“possible AF” or 8 
“unclassified”) and treatment decisions were at the discretion of the GP. 9 
To support screening, practices were provided with the following eHealth tools (Figure 1): 10 
• Screening prompt: an app located in a third-party hosting platform automatically 11 
extracted information from patients’ electronic medical records. Using this 12 
information in real-time, a prompt appeared when an eligible patient’s file was 13 
opened. The iECG automated screening result was also recorded in this app. 14 
• Electronic decision support (EDS): for those diagnosed with AF (either by screening 15 
or otherwise), the EDS app (also located on the third-party hosting platform) 16 
calculated their CHA₂DS₂-VA stroke risk score and made guideline recommendations 17 
regarding treatment. This app was part of the HealthTracker suite of cardiovascular 18 
quality improvement tools. 19 
• Tailored clinical audit data for QI reporting: customised, deidentified clinical audit 20 
data extracts were obtained monthly from participating practices. These data were 21 
used to report back to practices and included data on number and proportion 22 
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screened, the number of patients with new AF and the proportion treated according 1 
to guidelines.  2 
 3 
Reimbursement 4 
Practices were paid $1000 to cover study setup time and data extraction costs plus $10 per 5 
patient screened (paid per 100 patients to encourage greater numbers). This was intended 6 
to cover the costs of screening in the Australian “fee for service” context and to replicate a 7 
“real-world” fee if screening was covered by Medicare. Screening was free for patients, 8 
although any usual consultation fees applied.  9 
Data collection and analysis 10 
De-identified data extracts included demographic, iECG screening, medication and 11 
diagnostic information from the practices’ electronic patient records. The data extracts were 12 
designed to collect data for all “active patients” of the practices, i.e. patients who had 13 
attended at least 3 times in the past 2 years and once in the past 6 months. 14 
To provide additional context about broader screening and treatment trends, data from this 15 
study were compared with two other deidentified datasets: the “metropolitan group” and 16 
the “non-randomised control group”. These comparator datasets were collected from other 17 
Australian studies also using the HealthTracker app, with prospectively collected data using 18 
the same data extraction tool and data fields. The metropolitan group was from our 2018 AF 19 
screening study6 which included 8 metropolitan general practices. The non-randomised 20 
control group was comprised of 69 practices (64 metropolitan and 5 rural) that were using 21 
HealthTracker for general cardiovascular QI studies that did not involve AF screening. For 22 
the purposes of comparisons of treatment rates before and during the study period, the 23 
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non-randomised control group data were split into AF diagnoses prior to 1 January 2018 1 
(baseline treatment rate) and AF diagnosed on or later than 1 January 2018 (AF diagnosed 2 
during the study period). 3 
Descriptive analyses for the rural practices were carried out using Microsoft Excel. 4 
Descriptive analyses of non-randomised control data were performed using R Statistical 5 
Programming, V3.6.1.19 Comparisons of treatment rates between groups were calculated 6 
using Fisher’s exact test (2-sided p-values) performed using 2x2 contingency tables 7 
(GraphPad Prism V7.04, California, USA) with significance set a-priori at p<0.05. Although 8 
our protocol paper specified a chi-square test, Fisher’s exact test was used as it was more 9 
accurate with the small numbers involved. 10 
A detailed process evaluation was carried out using mixed methods, including semi-11 
structured interviews with selected practice staff. This evaluation examined outcomes 12 
related to implementation success and the acceptability/competing demands of the 13 
screening program. Methods and results of this evaluation have been described 14 
elsewhere.16 15 
Cost effectiveness analysis 16 
The iECG screening program was evaluated by comparing population-based AF screening to 17 
no screening from an Australian health funder perspective. The economic model developed 18 
in the SEARCH-AF20 pharmacy screening study was adapted to evaluate iECG screening in 19 
general practice. The model has previously been explained in detail.20 Briefly, =the model 20 
compares the cost of iECG screening, diagnosis and treatment in general practice to 21 
diagnosed AF in the unscreened population of Australian men and women aged 65-84 years. 22 
That is, it compares population-based AF screening to no screening. It assumes a ‘base rate’ 23 
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of AF (both diagnosed and unknown) and follows a cohort of the population aged 65-84 1 
years over 10 years with annual stroke events and all-cause mortality. 2 
Stroke costs included hospitalisation, rehabilitation and other ongoing medical costs. For 3 
this study, the model was updated to include the cost of an echocardiogram for those 4 
diagnosed, the cost of major bleeding episodes for those on OAC treatment and a treatment 5 
regimen consistent with current trends (i.e. including NOACs prescribed at rates observed in 6 
the current study). 7 
The model included the following key assumptions (full list included as Supplemental Table 8 
1):  9 
• The proportion screened was that observed in this study; 10 
• The prevalence of diagnosed AF in the population aged ≥65 years was 4.4%;3 11 
• The prevalence of unknown AF in the population aged ≥65years was 1.4%;3 12 
• OAC and antiplatelet treatment rates were as observed for all patients diagnosed 13 
during the study period (both screen-detected and otherwise detected); 14 
• The iECG test sensitivity was 97% and specificity was 92%; 15 
• The cost per screen was $20; and 16 
• For those diagnosed with AF, annual treatment and monitoring costs for those on 17 
OAC were AU$1063.78 = (warfarin) and AU$1401.73 (mean cost for NOACs), and 18 
included annual costs of medication, pathology, GP and specialist visits. 19 
 Costs for hospitalisation for stroke were obtained from Cadillhac et al21 and were updated 20 
to 2019 prices using the Australian Health Price Deflator Index. In addition, a present value 21 
of 5.09 quality adjusted life years (QALYs) (gained over a lifetime) was used for each 22 
ischemic stroke prevented by screening.21 23 
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Results are presented in Australian dollars as an incremental cost-effectiveness ratio (ICER) 1 
per stroke avoided and per QALY gained for population-based screening compared to no 2 
screening. Sensitivity analyses were also performed for different proportions of patients 3 
screened, and for price reductions in NOAC medicines. 4 
Outcomes 5 
Key study outcomes were:17 6 
• The proportion of screened patients with confirmed new AF 7 
• The proportion of AF and screened patients where the EDS was accessed 8 
• The proportion of AF patients diagnosed during the study period in the OAC 9 
recommended category (CHA₂DS₂-VA risk score ≥2)1 who were prescribed OAC 10 
according to guidelines  11 
• Baseline AF prevalence in patients aged ≥65 years compared to metropolitan and 12 
non-randomised control groups 13 
• New screen-detected AF incidence at the end of the study period in patients aged 14 
≥65 years, compared to metropolitan and non-randomised control groups 15 
• Rates of OAC and antiplatelet treatment at baseline and completion for patients in 16 
the OAC recommended category, compared to metropolitan and non-randomised 17 
control groups 18 
 19 
Results 20 
Screening, diagnosis and treatment 21 
Eight general practices were recruited and screened a total of 3,103 eligible patients (mean 22 
age 75.1 ± 6.8 years, 47% male) during the study period. The median screening period was 23 
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4.6 months (range 1.7-7.5 months). Practices screened a mean of 34% (median 35%) of 1 
eligible patients (range 9-51% per practice), with 4/8 practices screening >40% of eligible 2 
patients (Figure 2).  In general, screening was highest in the first 1-2 months, and declined 3 
thereafter. The mean proportion of all eligible patients who attended the practices during 4 
the study period was 94%. 5 
GPs (n=22) screened 31% (range 1-182 per GP) of patients and nurses (n = 40) screened 69% 6 
(range 1-192 per nurse). According to the iECG automated algorithm (as entered into the 7 
app by GPs/nurses), 83% of screenings were normal, 13% were unclassified and 4% were 8 
possible AF.  9 
In total, 36 (1.2%) new cases of screen-detected AF were confirmed (mean age 77.0 years, 10 
64% male, mean CHA₂DS₂-VA=3.2) (Table 1). The proportion of screen-detected AF patients 11 
with at least one non-age or gender risk factor was 83%, and the proportion in the OAC 12 
recommended category (CHA₂DS₂-VA≥2) was 94%. Characteristics and CHA₂DS₂-VA groups 13 
for those with screen-detected AF, otherwise-detected AF (during the study period) and 14 
those with AF detected before the study are presented in Table 1. 15 
OAC treatment rates of patients with AF with CHA₂DS₂-VA≥2 were 82% (screen-detected), 16 
75% (otherwise-detected during study period) and 74% (pre-existing AF), with no significant 17 
differences between treatment rates in the screen-detected and other groups (Table 1). The 18 
EDS was accessed for 54/1337 (4%) of all patients aged ≥65 with AF and for 4/36 (11%) of 19 
new screen-detected AF patients. 20 
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AF prevalence and treatment rates compared with metropolitan and non-randomised 1 
controls groups 2 
The baseline prevalence of AF in the rural, metropolitan and practices and non-randomised 3 
control groups ranged from 9-12% (Table 2).  4 
There were no significant differences between the rural and metropolitan practices’ 5 
treatment rates of those with AF detected prior to the study or during the study (screen-6 
detected and otherwise-detected) (Table 2). Likewise, the treatment rates in the rural 7 
practices were similar to those in the non-randomised control practices at baseline and 8 
during the study period (Table 2). The OAC treatment rates in all 3 cohorts tended to 9 
increase from baseline (Table 2), in contrast to antiplatelets. 10 
Cost-effectiveness analysis 11 
Our cost-effectiveness modelling showed that for population-based AF screening for 12 
Australian men and women aged 65-84 years, assuming a 34% screening participation rate, 13 
with a treatment rate of 82%, and test sensitivity 97% and specificity of 92%, the ICER per 14 
QALY gained was AU$16,578 and the ICER per stroke avoided was AU$84,383 compared to 15 
no screening.  16 
Increasing the screening participation rate has a negligible effect on the ICER but 17 
substantially increases the number of strokes prevented, i.e. effectiveness (Table 3). 18 
Increasing the screening participation rate from 34% to 50% raises the number of strokes 19 
prevented from the base case of 147 per year to 216 per year (or 1467 to 2157 over 10 20 
years).  With a 75% screening participation rate, a total of 324 strokes are prevented each 21 
year (or 3235 strokes over 10 years) when compared to the no screening scenario. For 22 
population-based screening, lowering the cost of NOAC treatment decreases the ICER per 23 
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QALY gained to AU$14,997 (12.5% price reduction) or AU$13,416 (25% price reduction) 1 
compared to no screening. 2 
Discussion 3 
This study investigated the impact of an AF screening program in rural general practices 4 
using a smartphone iECG together with a suite of custom-designed eHealth tools designed 5 
to increase the proportion screened and treated for AF in accordance with guidelines.  GPs 6 
and nurses at participating practices screened a total of 3103 eligible patients and 36 (1.2%) 7 
new cases of AF were confirmed, with 82% prescribed OAC according to guidelines.  8 
This study featured a unique suite of integrated, customised eHealth tools, to support all 9 
stages of AF screening and treatment in general practice. These tools were refined following 10 
our metropolitan study,6 and included an automated screening prompt (with improved 11 
visibility and reliability), an EDS app to guide treatment, deidentified data extracts and with 12 
regular QI ‘audit and feedback’ reporting to practices. We are not aware of any other 13 
studies that include tools to cover all stages of AF screening and treatment, including 14 
customised feedback. In particular, the refined screening prompt and the improved QI 15 
reporting were useful and motivating for participating GPs and nurses.16 16 
Proportion screened and treated 17 
Practices screened 34% of eligible patients who attended during the study period, which is 18 
substantially higher than the 16% achieved in our metropolitan study.6 Half of the study 19 
practices were able to screen >40% of eligible patients, although 51% was the maximum 20 
reached. It appeared that even practices with very broad uptake and high motivation across 21 
staff were not able to capture more than 50% of eligible patients, which GPs and nurses 22 
indicated was largely due to time constraints and technical issues (eg difficulty taking a 23 
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reading on some patients).16 Key features of the most successful practices included 1 
leadership from a senior GP ‘screening champion’, clear protocols for follow-up of abnormal 2 
results for nurse-led screening and allocating sufficient staff time for screening. These are 3 
discussed in detail in our qualitative realist evaluation.16 4 
A recent study of AF screening in 184 Canadian practices was able to screen 42% of eligible 5 
patients.22 In addition, a study from the Netherlands where patients aged ≥65 years were 6 
screened in 10 general practices during influenza vaccination sessions captured 35% of 7 
eligible patients, which is almost identical to our study.23 These results suggest 40-50% may 8 
be a ‘ceiling’ of eligible patients captured by an opportunistic screening program in general 9 
practice. 10 
As with the metropolitan study, treatment rates were high at baseline (>70%), compared to 11 
historical Australian data, and increased during the study. The treatment rates were highest 12 
for screen-detected AF (>80%). These treatment rates and trends very similar to those in the 13 
non-randomised control practices. These rates are higher than previously reported in 14 
Australia, which were around 55-60%24 prior to the introduction of NOACs (preferred by the 15 
Australian guidelines1). Our results show a similar trend to recent European treatment rates 16 
of around 65%-80%8, 25, 26 since the introduction of NOACs. 17 
Our results also show a decline in antiplatelet prescription for those not on OAC. Of the 18 
patients diagnosed during the study period (aged ≥65 years with CHA₂DS₂-VA≥2) who were 19 
not prescribed OAC (n=20), only a minority were prescribed antiplatelets alone (n=7) with 20 
the remainder on no therapy (n=13). Of the 7 patients prescribed antiplatelets alone, 2 of 21 
these patients were prescribed antiplatelets before being diagnosed with AF (one of whom 22 
had cardiovascular disease) and another 3 of these patients also had cardiovascular disease, 23 
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which may be the reason antiplatelets were prescribed. This suggests that prescription of 1 
antiplatelet alone for AF may be declining, as was recently reported in a US study,27 and that 2 
effectively the prescribing decision is becoming “OAC or no treatment”. 3 
Rural setting 4 
This study extends the evidence base in rural areas and shows a screening program in the 5 
rural general practice setting can successfully screen a large number of eligible AF patients 6 
with guideline-indicated treatment rates over 80% for screen-detected AF cases. A 7 
screening program using pulse palpation in rural general practice in Ireland achieved similar 8 
reach to our study (30% of the general practice population aged ≥65 years screened) 9 
although OAC treatment rates were lower (65%).28 The authors noted important differences 10 
regarding the density of population in rural studies compared to metropolitan, with 11 
implications for rural patients’ access to primary and secondary care.  12 
Prevention programs suitable for rural areas are particularly important, given that people 13 
living in these areas tend to have worse cardiovascular outcomes and less access to 14 
specialist medical services.9 Rural general practice is potentially an ideal setting for 15 
implementation of innovative primary care-based cardiac programs, such as ours, which 16 
contribute to upskilling GPs in cardiac care, training nurses to provide cardiac 17 
education/screening, and use of novel technology. 18 
Cost-effectiveness 19 
Our cost-effectiveness modelling showed that for population-based AF screening in general 20 
practice for Australian men and women aged 65-84 years, the ICER per QALY gained was 21 
AU$16,578 and the ICER per stroke avoided was $84,383 compared to no screening. 22 
Increasing the proportion screened from 34% to 75% would prevent an additional 177 23 
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strokes per year (or 1,768 strokes over 10 years) with a negligible effect on the ICER. These 1 
figures are higher than for SEARCH-AF,20 largely driven by increased uptake of OAC 2 
treatment rates and in particular, the higher prescription rates of NOACs. The increased 3 
proportion of people treated with OAC reduces the ICER, although this is offset by the 4 
higher cost of treatment with NOACs. These figures are well within accepted thresholds of 5 
Australian government health expenditure.29 This is consistent with several other studies, 6 
which found AF screening to be cost-effective30 or even cost-saving31.  7 
Importantly, while we were able to screen 34% of eligible people with these tools (and have 8 
suggested that 40-50% may be a ‘ceiling’ of patients captured with opportunistic screening 9 
programs), these analyses highlight the impact of increasing the proportion screened in 10 
terms of stroke prevention and the need to consider new approaches to break the 40-50% 11 
barrier. 12 
Limitations 13 
The proportion of “non-normal” results according to the iECG device algorithm was 14 
relatively high at 17% (‘possible AF’ 4%, ‘unclassified’ 13%). This added to the workload 15 
substantially for practices, as was also noted in a recent Canadian study,22 as all of these 16 
patients require some degree of follow-up. In relation to the ‘possible AF’ readings, it is 17 
likely that some were paroxysmal AF (AF not present on a subsequent 12 lead ECG) or false 18 
positives (e.g. due to sinus arrhythmia, multiple atrial ectopics or a poor quality trace). It is 19 
also possible that some AF diagnoses were not recorded in the clinical system (see below). 20 
In relation to the ‘unclassified’ results, previous studies have usually reported lower rates 21 
closer to 10%.6, 14 Improvements in the device algorithm (eg to identify sinus 22 
tachycardia/bradycardia) and training staff in techniques to take clearer readings will reduce 23 
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this burden. We note the research team were not able to review the iECGs, and relied on 1 
GPs/nurses to manually enter the device’s interpretation into the AF app. The iECG 2 
automated algorithm has been  reported to have a sensitivity of 97% and specificity of 3 
92%.20 4 
The EDS was only used for a low proportion of patients. This is probably because it was in a 5 
separate app and was not accessed by GPs as it required extra clicks. Ideally, an EDS would 6 
need to be a more integral part of the electronic medical record system. Alternatively, an 7 
automatic calculation of patients’ CHA₂DS₂-VA scores in the electronic medical record would 8 
assist, particularly if it included an alert to review treatment when the score changed 9 
(especially when it exceeds a treatment-recommendation threshold). 10 
The study relied on deidentified data collected from practices. This was routinely collected 11 
general practice data, with all its inherent limitations. For example, if GPs recorded a 12 
diagnosis of AF in the free-text notes section instead of adding it as a condition from a drop-13 
down list, this would not be caught in our data, meaning our figures may underestimate the 14 
true rate of AF detected during the study.  In addition, these data were limited to ‘active 15 
patients’ due to the definition in the data collection tool. ‘Active patients’ were defined as 16 
those who had attended the practice at least three times in the past 2 years and once in the 17 
last 6 months. Therefore, our data may be biased towards people with more chronic 18 
conditions requiring more frequent attendance at the practice. 19 
Conclusions 20 
An AF screening program in rural general practices, supported by eHealth tools, screened 21 
34% of eligible patients, with 82% of new screen-detected cases treated according to 22 
guideline. Half the practices screened 40-50% of eligible patients, suggesting this may 23 
19 
 
represent a ‘ceiling’ of patients captured by opportunistic AF screening programs. OAC 1 
treatment rates were higher than previous studies at baseline and were trending upwards 2 
during the study. Increasing the proportion screened would prevent many more strokes 3 
with minimal change to the ICER. This may require new methods to break through the 4 
‘ceiling’ captured by numerous opportunistic programs. eHealth tools, particularly 5 
customised data reports as part of an audit and feedback system, may be a valuable 6 
addition to future screening programs.  7 
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Figure legends 1 
Figure 1 – Screening process and eHealth tools adapted from our 2018 metropolitan study6  2 
Figure 2 – Screening flowchart  3 
 4 




Table 1 2 
 3 









before study  
 (n=36) (n=58) (n=1243) 
Age in years (mean ± SD) 77.0 ± 6.1 77.0 ± 8.4 79.2 ± 7.8 
Male, n (%) 23 (64%) 32 (55%) 662 (53%) 
Mean CHA₂DS₂-VA 3.2 3.3 3.7 
CHA₂DS₂-VA ≥2, n (% of total)   34 (94%) 55 (95%) 1223 (98%) 
CHA₂DS₂-VA ≥2 and prescribed 
OAC, n (% of those with CHA₂DS₂-
VA ≥2) 




≥1 non-age or gender risk factors, 
n (% of total)   
30 (83%) 54 (93%) 1178 (95%) 
AF, atrial fibrillation; SD, standard deviation; CHA₂DS₂-VA: C, congestive heart failure/left 5 
ventricular dysfunction; H, high blood pressure; A2, age >75 years; D, diabetes; S2, 6 
stroke/transient ischemic attack/thromboembolism; V, vascular disease [coronary artery 7 
disease, myocardial infarction, peripheral artery disease, aortic plaque]; A, age 65 – 74 8 
years; † p-value for comparison to screen-detected AF 9 
25 
 
Table 2 1 
 2 











Total active* patients aged ≥65 years 10,896 13,679 30,116 
Baseline AF prevalence  12% 11% 9% 
Baseline: AF detected prior to study with CHA₂DS₂-VA≥2 
Total, n 1223 1306 1875 




Prescribed antiplatelet alone, n (%) 178 (15%) 213 (16%) 248 (13%) 
Not prescribed OAC or antiplatelet, n 
(%) 
137 (11%) 160 (12%) 177 (9%) 
Screen-detected AF during study period with CHA₂DS₂-VA≥2 
Total, n 34 18 N/A 
Prescribed OAC, n (%)  28 (82%) 15 (83%) 
p>0.999† 
N/A  
Prescribed antiplatelet alone, n (%) 1 (3%) 1 (6%) N/A 
Not prescribed OAC or antiplatelet, n 
(%) 












All AF detected during study period (screen-detected + otherwise-detected) with CHA₂DS₂-
VA≥2 
Total, n 89 64 399 




Prescribed antiplatelet alone, n (%) 7 (8%) 3 (5%) 29 (7%) 
Not prescribed OAC or antiplatelet, n 
(%) 
13 (15%) 7 (11%) 37 (9%) 
*active patients are those who attended the practice at least 3 times in the last 2 years and 1 
once in the last 6 months 2 
† p-value for comparison to rural practices 3 
AF, atrial fibrillation; OAC, oral anticoagulant; CHA₂DS₂-VA: C, congestive heart failure/left 4 
ventricular dysfunction; H, high blood pressure; A2, age >75 years; D, diabetes; S2, 5 
stroke/transient ischemic attack/thromboembolism; V, vascular disease [coronary artery 6 
disease, myocardial infarction, peripheral artery disease, aortic plaque]; A, age 65 – 74 7 
years. 8 
  9 
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Table 3 1 
Table 3: Cost effectiveness of population-based AF screening compared to no screening 2 




    
Screening participation rate 34% 50% 60% 70% 75% 
Number of strokes prevented 1467 2157 2588 3020 3235 
Net cost [ICER] per stroke 
prevented compared to no 
screening 
$84,383 $83,304 $82,922 $82,649 $82,540 
Net cost [ICER] per QALY 
gained compared to no 
screening 
$16,578 $16,366 $16,291 $16,238 $16,216 
NOAC price reduction - 12.5% 25%   
Screening participation rate 34% 34% 34%   
Number of strokes prevented 1467 1467 1467   
Net cost [ICER] per stroke 
prevented compared to no 
screening 
$84,383 $76,336 $68,289 
  
Net cost [ICER] per QALY 
gained compared to no 
screening 




ICER, incremental cost effectiveness ratio; QALY, quality adjusted life year; NOAC, novel 1 
anticoagulant; $ = AU$ 2 
 3 
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Figures  5 




Figure 1 – Screening process and eHealth tools adapted from our 2018 metropolitan study6  10 
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Figure 2 1 
 2 
Figure 2 – Screening flowchart  3 
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